2020 Tri-Agency Award Recipients

The Tri-Agency Awards are awarded by the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC). These awards support outstanding students pursuing a doctoral or master’s degree in a health-related field. Jaimy Fischer: SSHRC Joseph-Armand Bombardier Canada Graduate Scholarship (Doctoral) Jaimy Fischer is a Michif with Red River…
Read More

New Study Finds Sex Differences in Adult Neurogenesis in the Hippocampus

Like many areas of science, neurogenesis is one where little work has been done looking at sex differences. Neurogenesis is the process where new neurons are formed in the brain, which happens in the adult hippocampus. Previous research in this area has largely focused on male subjects, which has prevented researchers from understanding how this process might differ in females.…
Read More
UBC’s Dr. Mel Krajden, professor in the department of pathology and laboratory medicine, is one of 13 individuals being recognized for this year’s Order of British Columbia, one of the province’s highest honours. Dr. Krajden, also the medical director of the Public Health Laboratory and medical head of hepatitis at the B. C. Centre for Disease Control (BCCDC), has been central to…
Read More
Every year, cervical cancer kills about 400 Canadian women. Worldwide, cervical cancer kills one woman every two minutes. But cervical cancer is a completely preventable illness. The HPV vaccine, offered to all students in Grade 6, and an accurate test that women can take themselves is enough to eliminate the disease altogether. Two Canadian scientists are working hard to bring…
Read More
The COVID-19 pandemic has transformed how we all live and work. It’s also changed how we do science. At Providence Health Care, our research community has been faced with shuttered labs and offices, financial uncertainty, and a rapid shift to virtual research environments. In this Q&A series, we’re asking PHC researchers and research staff to reflect on their experience over…
Read More
Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from SFU chemist Robert Britton and his international team. For the past 50 years, scientists have used manmade, synthetic, nucleoside analogues to create drug therapies for diseases that involve the cellular division and/or the viral reproduction of infected cells. These diseases include hepatitis, herpes simplex,…
Read More
This work, describing siRNA targeting FXIII-B (siFXIIIB), is the first pharmacologic approach for long-acting, reversible, and targeted decrease of FXIII-A activity in vivo. It enables the study of FXIII in a wide range of disease models, including in animals not amenable to genetic FXIII knockout. FXIII is considered a therapeutic target for preventing thrombosis, and siFXIIIB overcomes limitations of current antithrombics and thrombolytics by specifically enhancing endogenous fibrinolysis.
Read More
Genome British Columbia (Genome BC) today announced the appointment of Dr. Federica Di Palma as Chief Scientific Officer (CSO) & Vice President, Sectors. She brings over 20 years of international experience in science, technology and innovation with an emphasis on understanding complex biological systems. Dr. Di Palma’s deep understanding of genomics and strategic expertise will make her an essential member…
Read More
AbCellera today announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as a potential treatment and prophylaxis for COVID-19, has progressed to Phase 3 clinical trials. A first-of-its-kind, the Lilly-sponsored trial will use customized mobile research…
Read More
In some Huntington disease (HD) patients, the “loss of interruption” (LOI) variant eliminates an interrupting codon in the HTT CAG-repeat tract, which causes earlier age of onset (AOO). The magnitude of this effect is uncertain, since previous studies included few LOI carriers, and the variant also causes CAG size misestimation. We developed a rapid LOI detection screen, enabling unbiased frequency estimation among…
Read More